Compare EIG & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIG | CTMX |
|---|---|---|
| Founded | 2000 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 754.0M | 977.1M |
| IPO Year | 2006 | 2015 |
| Metric | EIG | CTMX |
|---|---|---|
| Price | $43.33 | $3.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $12.10 |
| AVG Volume (30 Days) | 161.4K | ★ 2.8M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.99% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $858,700,000.00 | $76,201,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.26 | $7.61 |
| P/E Ratio | $83.29 | ★ $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $35.73 | $1.72 |
| 52 Week High | $49.39 | $8.21 |
| Indicator | EIG | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 33.74 |
| Support Level | $41.01 | $3.39 |
| Resistance Level | $43.31 | $3.91 |
| Average True Range (ATR) | 1.17 | 0.22 |
| MACD | 0.11 | -0.04 |
| Stochastic Oscillator | 93.85 | 20.42 |
Employers Holdings Inc is a provider of workers' compensation insurance and services focused on small and mid-sized businesses engaged in low-to-medium hazard industries. Its customers are employers, and the insurance premiums that those employers pay to account for company revenue. Substantially all of the remaining revenue is generated through investments. The company operates exclusively in the United States, and it generates more than half of its business in California. By industry, the company has exposure to restaurants, which account for roughly a fourth of the total premiums the company earns. It operates as a single reportable segment, Insurance Operations through its wholly owned subsidiaries.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.